Resverlogix Presents at BIO CEO & Investor Conference

TSX Exchange Symbol: RVX

CALGARY, Feb. 10, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) presented at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 held at the Waldorf Astoria in New York City.  The presentation was a corporate update on the proposed Phase III clinical trial and business structure options.

The presentation was archived and can be viewed using the following link:

About the BIO CEO & Investor Conference
The 17th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies.  The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2014 CEO & Investor Conference featured 1,820 partnering meetings, 149 company presentations, and 1,400 attendees, over half of which were investors. 

About Resverlogix
Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit We can be followed on Twitter @Resverlogix_RVX and our blog at

For further information, please contact:

Company Contacts:

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252

Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: 403-254-9252


Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners, LLC
Phone: 212 845 4251
Phone: 212-845-4272

SOURCE Resverlogix Corp.


Organization Profile

Resverlogix Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890